Status:
TERMINATED
An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Epilepsy
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The main purpose of this trial is to allow continued access to pregabalin to Canadian subjects who participated in global pregabalin epilepsy studies 1008-010; 1008-035; 1008-114 and 1008-164 and to c...
Eligibility Criteria
Inclusion
- Must have completed Pfizer open-label studies 1008-010; 1008-035; 1008-114 or 1008-164 and wishes to continue receiving open-label pregabalin
- Must have responded favorably to pregabalin in Pfizer open-label study 1008-010, 1008-035, 1008-114 or 1008-164 and in the clinical opinion of the investigator continued treatment with pregabalin is in the the patient's best medical interest
Exclusion
- Is pregnant or is considering becoming pregnant during the course of the study
- Experienced a serious adverse event during open-label Pfizer study 1008-010, 1008-035, 1008-114 or 1008-164
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2011
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00372528
Start Date
March 1 2007
End Date
October 1 2011
Last Update
January 26 2021
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Calgary, Alberta, Canada, T2N 2T9
2
Pfizer Investigational Site
Halifax, Nova Scotia, Canada, B3H 3A7
3
Pfizer Investigational Site
Barrie, Ontario, Canada, L4M 4S5
4
Pfizer Investigational Site
Toronto, Ontario, Canada, M5C 1R6